Glucose uptake of the spinal cord in patients with multiple sclerosis detected by ¹⁸F-fluorodeoxyglucose PET/CT after walking.

Abstract

Case report. To determine [(18)F]-fluorodeoxyglucose ([(18)F]-FDG) uptake in the spinal cord of patients with multiple sclerosis (MS) was compared with healthy controls after treadmill walking. Colorado Translational Research Imaging Center, University of Colorado School of Medicine, Aurora, CO, USA. Eight mildly disabled patients with MS and eight healthy subjects performed 15 min of treadmill walking at a self-selected pace. Two minutes after walking began, each participant was injected with ≈8 mCi of [(18)F]-FDG into a catheter inserted into an antecubital vein. Immediately after walking positron emission tomography/computed tomography (PET/CT) imaging was performed on each participant. Images were analyzed to determine [(18)F]-FDG uptake within the spinal cord. Total spinal cord [(18)F]-FDG uptake was lower in patients with MS (1.48±0.36 and 1.55±0.33, P=0.04), specifically within the thoracic (1.32±0.27 and 1.41±0.24, P<0.01) and the lumbar (1.58±0.40 and 1.89±0.43, P=0.04) spinal cord regions. This is the first report of [(18)F]-FDG uptake in the spinal cord of patients with MS. The decreased [(18)F]-FDG uptake within the thoracic and lumbar spinal cord regions could be associated with autonomic nervous system and walking/motor dysfunctions that are often seen in patients with MS. PET/CT imaging with [(18)F]-FDG is highly useful for the demonstration of impaired glucose metabolism in the spinal cord of patients with MS.